LOGEX tracks effects of COVID-19 on regular hospital care through detailed monthly benchmark reporting

Like in the rest of the world, the care for COVID-19 patients has put great pressure on Dutch hospitals: ICU and ward capacity is rationed for COVID-19 care resulting in the delay or even cancellation of regular treatments on a large scale. The delay of these treatments is resulting in the build-up of a healthcare demand ‘reservoir’. 

Dutch hospital production trend by type of care

Over the past year, many hospitals have struggled with understanding the implications of COVID-19 on their patients and organization. Since the start of the COVID-19 pandemic, LOGEX has shared in-depth (monthly) reports with its hospital customers in The Netherlands, analyzing the progression of regular care production on a national and regional level, as well as the implications on the hospital’s organization and financial position. In these reports, LOGEX has helped hospitals focus on the following elements: 

1. Monitoring hospital production of regular care

  • Understanding the cumulative effects of continued (and halted) treatments on a weekly level, broken down by healthcare cluster (acute care, oncology, chronic diseases, elective treatments), per specialism and diagnose group
  • Developing insights on patient characteristics to understand potential risks, enabling hospitals to respond or correct where needed
  • Establishing national and regional benchmarks to help better understand the hospital’s local trends

2. Estimating and forecasting the ‘reservoir’ of impacted regular care

  • Quantifying and forecasting the cumulative (financial and organizational) impact of healthcare not provided, through historical trend analysis 
  • Estimating the share of treatments not provided, that are not likely return to the hospital. This helps develop a view on the nett remaining healthcare demand that needs to be recovered by the hospital
  • Benchmarking the local ‘reservoir’ buildup with the national trend, to better understand the hospital’s position

3. Understanding the implications of hospital resources

  • Quantifying the impact of delayed treatments that will likely need to be recovered on hospital resources and infrastructure (staff, diagnostics, OR and ward capacity, etc.)
  • Understanding what delayed treatments can be recovered within the existing hospital infrastructure and capacity, in addition to the normal healthcare demand (What are the limitations for recovering delayed treatments? What are likely effects on the hospital’s waiting lists? etc.)

4. Providing tangible guidelines for Appropriate Care initiatives that may help free hospital capacity

  • Establishing a clear list of Appropriate Care topics where hospitals are most likely to improve efficiency and free up capacity for recovering delayed treatments
  • With help of known best practices, LOGEX quantified the potential impact of the various initiative on hospital resources through benchmark analysis indicating the extent of Practice and Process variation between hospitals

Payer <> Provider alignment

  • Understanding the financial implications of healthcare not delivered, as well as the treatments that are likely to be recovered. LOGEX analyzed the effects of COVID-19 on the hospital’s revenues and cost base, to reflect on the implications for existing payer<>provider agreements 
  • The analyses conducted by LOGEX helped support the development of a national COVID-19 compensation scheme between the Association of Health Insurers (Zorgverzekeraars Nederland, ZN) and the Dutch Association of Hospitals (Nederlandse Vereniging van Ziekenhuizen, NVZ) to neutralize the financial effects of COVID-19 and ensure financial stability

Forbes picks up on work done by Financial Control for the Dutch Association of Hospitals (NVZ)

At the beginning of July, health insurers struck a deal with several national hospital associations on covering both the costs of COVID-19 care and hospital losses. The agreement stipulates that health insurers “neutralize” the budgetary effects of the COVID-19 crisis on hospitals’ capacity to generate revenue while reimbursing net, additional costs incurred by hospitals as a result of the coronavirus epidemic. The agreement is estimated to cost insurers around €4 billion.

At the request of the Dutch Association of Hospitals (NVZ), LOGEX has supported as a technical advisor to identify any effects and risks of the agreement. During this process, LOGEX worked closely with 8 hospitals to evaluate and understand risks and impacts on returns, costs, and results. Currently, we are active in > 40 hospitals to support them in their individual processes.

Read the full article on the Forbes website.

LOGEX, V2H, Prodacapo and Ivbar join forces to turn data into better healthcare in Europe

Leading European healthcare data analytics providers from the Netherlands, Sweden and Finland have joined forces to form the LOGEX Group, creating a European market leader in advanced analytics solutions for the healthcare industry.

Effective September 2020, all healthcare analytics software and services provided by LOGEX, Ivbar and Prodacapo will be delivered under the name LOGEX.

The announcement formalizes their intention to move forward as a single company, united by a single mission: to turn data into better healthcare.

A unified response in a time of challenges

Bringing together capabilities from European market leaders in healthcare analytics, LOGEX expands its product offering to deliver insights in three key areas of healthcare data: Financial, Value, and Outcomes.

Leveraging these insights, decision-makers are empowered to take strategic action that leads to the best possible outcomes at the lowest possible cost.The expansion in expertise, talent, and geographic scope likewise enables LOGEX to offer healthcare providers, payers and organizers an unmatched ability to learn, collaborate and benchmark with peers internationally. As healthcare faces a time of unprecedented challenge, the formation of the LOGEX Group comes as a unified response to the increasingly complex needs of the healthcare industry.

This enables LOGEX to deliver actionable insights to stakeholders at every level of the healthcare system, at a time when clarity is more critical than ever.

Customers will benefit from a more versatile product portfolio that meets a broader spectrum of their needs as they strive to drive improvements in their operations.

Philipp Jan Flach, CEO of the LOGEX Group

New brand name, same functionalities

While existing and future software will bear the brand name LOGEX, customers can expect unchanged functionalities from their current suite of analytics tools, as well as uninterrupted service from the teams that currently work with them.

All contractual and legal responsibilities from existing contracts effectively switch over to LOGEX. Data remains secured at the highest level, compliant to all relevant data privacy standards, and will continue to do so. LOGEX will be headquartered in Amsterdam, with over 350 international experts working in nine countries across Europe.

About LOGEX  

As Europe’s leading healthcare analytics expert, LOGEX turns data into better healthcare. We offer advanced analytics solutions that transform data into actionable insight, bringing clarity to decisions that lead to the best possible outcomes at the lowest possible cost.

    Request demo

    Please fill in the form below and select which domains you’re interested in. We contact you as soon as possible to schedule a demo.